Remora Biotech

Remora Biotech is a Swiss life sciences company builder and investment platform focused on creating and advancing biotherapy companies rather than developing a single in-house therapeutic asset. The firm identifies early-stage science, forms venture companies around promising programs, and supports them through validation, company formation, development, and strategic partnering. Its current focus areas include immunotherapy, vectorized therapies such as antibody-drug conjugates and radiopharmaceuticals, regenerative and aesthetic biotherapies, and cell & gene therapy. Remora appears to operate primarily as a portfolio-based biotech incubator with centralized scientific, legal, financial, and operational support. A notable portfolio outcome is Fastox Pharma, which was acquired by AbbVie in 2024 for its botulinum toxin booster technology.